Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 23 11:41AM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.34 Insider Own13.95% Shs Outstand146.38M Perf Week-5.86%
Market Cap143.32M Forward P/E- EPS next Y-0.30 Insider Trans-1.10% Shs Float125.96M Perf Month25.40%
Income-35.82M PEG- EPS next Q-0.06 Inst Own36.37% Short Float8.31% Perf Quarter-22.91%
Sales13.48M P/S10.63 EPS this Y75.82% Inst Trans-6.50% Short Ratio4.98 Perf Half Y147.25%
Book/sh0.31 P/B3.17 EPS next Y-13.53% ROA-50.43% Short Interest10.47M Perf Year-24.10%
Cash/sh0.24 P/C4.13 EPS next 5Y- ROE-115.69% 52W Range0.36 - 1.92 Perf YTD35.99%
Dividend Est.- P/FCF- EPS past 5Y-19.79% ROI-62.57% 52W High-49.01% Beta-0.42
Dividend TTM- Quick Ratio4.22 Sales past 5Y16.77% Gross Margin33.87% 52W Low171.97% ATR (14)0.09
Dividend Ex-DateApr 28, 2014 Current Ratio4.72 EPS Y/Y TTM80.03% Oper. Margin-320.41% RSI (14)53.39 Volatility10.60% 10.16%
Employees- Debt/Eq0.31 Sales Y/Y TTM-36.67% Profit Margin-265.74% Recom1.60 Target Price3.40
Option/ShortYes / Yes LT Debt/Eq0.27 EPS Q/Q85.73% Payout- Rel Volume0.16 Prev Close0.96
Sales Surprise36.67% EPS Surprise-31.33% Sales Q/Q-37.21% EarningsMay 08 BMO Avg Volume2.10M Price0.98
SMA208.58% SMA50-3.76% SMA20012.74% Trades Volume125,618 Change2.00%
Date Action Analyst Rating Change Price Target Change
May-14-24Initiated B. Riley Securities Buy $5
Mar-28-24Initiated Raymond James Outperform $3
Jun-07-23Upgrade Jefferies Underperform → Hold $1
Apr-13-21Initiated Jefferies Buy $19
Feb-09-21Reiterated H.C. Wainwright Buy $12 → $17
Jan-21-20Reiterated H.C. Wainwright Buy $4.50 → $6
Mar-20-19Initiated Oppenheimer Outperform $5
Jul-03-18Initiated Maxim Group Buy
Jul-02-24 08:30AM
Jun-26-24 07:53AM
Jun-24-24 08:30AM
Jun-18-24 04:05PM
Jun-17-24 04:45PM
08:30AM Loading…
Jun-10-24 08:30AM
May-22-24 08:30AM
May-15-24 08:30AM
May-14-24 08:30AM
May-13-24 10:43AM
May-09-24 03:01AM
May-08-24 08:39AM
May-02-24 08:30AM
May-01-24 08:30AM
09:55AM Loading…
Apr-30-24 09:55AM
Apr-25-24 08:30AM
Apr-17-24 12:00PM
Apr-01-24 04:05PM
Mar-22-24 04:05PM
Mar-15-24 01:46PM
Mar-13-24 07:30AM
Mar-12-24 08:00AM
Feb-27-24 07:15PM
Feb-20-24 08:30AM
Feb-13-24 09:35AM
Feb-09-24 10:46AM
Feb-08-24 10:19PM
06:30AM Loading…
Feb-06-24 08:30AM
Feb-01-24 10:00AM
Jan-31-24 08:30AM
Jan-25-24 08:30AM
Jan-08-24 08:30AM
Dec-19-23 08:30AM
Dec-14-23 09:00AM
Dec-13-23 04:01PM
Dec-07-23 06:00AM
Oct-05-23 07:18AM
Oct-04-23 08:30AM
Sep-26-23 08:30AM
Sep-20-23 08:30AM
Sep-11-23 07:00AM
Aug-30-23 08:30AM
Aug-11-23 08:15AM
Aug-10-23 07:50AM
Aug-03-23 08:30AM
Jun-21-23 08:30AM
Jun-01-23 08:30AM
May-24-23 08:30AM
May-11-23 08:09AM
May-09-23 11:15AM
May-04-23 10:00AM
May-03-23 08:30AM
Apr-27-23 06:45AM
Apr-20-23 06:45AM
Apr-19-23 08:30AM
Apr-12-23 09:35AM
Apr-11-23 03:49PM
Apr-04-23 08:30AM
Mar-27-23 06:37AM
Mar-14-23 01:36PM
Mar-07-23 08:30AM
Mar-03-23 11:27AM
Mar-02-23 04:01PM
Feb-14-23 06:06AM
Feb-10-23 03:11PM
Feb-09-23 07:45AM
Jan-26-23 08:30AM
Jan-17-23 05:32AM
Jan-10-23 08:30AM
Dec-29-22 05:57AM
Dec-10-22 09:45AM
Dec-08-22 01:59PM
Dec-07-22 08:15AM
Dec-05-22 08:00AM
Dec-02-22 09:00AM
Nov-28-22 08:30AM
Nov-23-22 05:54PM
Nov-22-22 09:15AM
Nov-21-22 06:10PM
Nov-13-22 07:46AM
Nov-11-22 03:15PM
Nov-10-22 04:11PM
Nov-09-22 08:55PM
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company's drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BARNETTE K GARYChief Scientific OfficerMay 24 '24Buy1.345,0006,6965,000May 24 06:57 PM
FISCH HARRYChief Corporate OfficerMay 24 '24Buy1.254,0005,000774,736May 28 05:04 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 24 '24Sale1.2363,37978,1026,942,709May 24 06:51 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 23 '24Sale1.353004057,006,088May 24 06:51 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 22 '24Sale1.396,5049,0187,006,388May 24 06:51 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 17 '24Sale1.3228,06636,9887,012,892May 17 07:41 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 16 '24Sale1.4159,78884,1287,040,958May 17 07:41 PM
FISCH HARRYChief Corporate OfficerMay 15 '24Buy1.496,7119,999770,736May 17 07:46 PM
STEINER MITCHELL SHUSTERPresident and CEOMay 15 '24Sale1.5084,021125,8137,100,746May 17 07:41 PM